According to results, treatment-emergent adverse events occurred in 76.5% of
patients in the Dialive group and 80% of
patients in the standard of care group, with no significant differences between groups (95% CI, 0.35-0.29). At least one serious adverse event occurred in 64.7% and 53.3% (95% CI, 0.29-0.51), respectively.
Of the serious adverse events in the Dialive group, researchers considered 41.2% related to treatment.